Literature DB >> 19524111

Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P).

Karen Koopman1, Nathalie Le Bastard, Jean-Jacques Martin, Guy Nagels, Peter P De Deyn, Sebastiaan Engelborghs.   

Abstract

To establish diagnostic accuracy (acc) and optimal cut-off levels of CSF tau phosphorylated at threonine 181 (P-tau(181P)) for discriminating Alzheimer's disease (AD) from non-AD dementias in autopsy-confirmed dementia patients, CSF levels of beta-amyloid peptide (Abeta(1-42)), total tau protein (T-tau) and P-tau(181P) from patients with definite AD (n=95) and non-AD dementias (n=50) were determined with single-parameter ELISA kits. Optimal P-tau(181P) cut-off levels for differentiating AD from pooled non-AD dementias, dementia with Lewy bodies (DLB) and frontotemporal dementia (FTD) were 50.4pg/mL (acc=0.73), 52.8pg/mL (acc=0.73) and 35.3pg/mL (acc=0.90), respectively. The optimal CSF P-tau(181P) cut-off level for discriminating AD from non-AD dementias was 50.4pg/mL. Optimal CSF P-tau(181P) cut-off levels differed between non-AD diagnostic dementia categories.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19524111     DOI: 10.1016/j.neuint.2009.02.017

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  36 in total

1.  Amyloid imaging in dementias with atypical presentation.

Authors:  David A Wolk; Julie C Price; Charles Madeira; Judy A Saxton; Beth E Snitz; Oscar L Lopez; Chester A Mathis; William E Klunk; Steven T DeKosky
Journal:  Alzheimers Dement       Date:  2012-01-30       Impact factor: 21.566

2.  Tau and Amyloid-β Cerebrospinal Fluid Biomarkers have Differential Relationships with Cognition in Mild Cognitive Impairment.

Authors:  Charles B Malpas; Michael M Saling; Dennis Velakoulis; Patricia Desmond; Terence J O'Brien
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

3.  [Clinically validated molecular biomarkers of neurodegenerative dementia].

Authors:  J Wiltfang
Journal:  Nervenarzt       Date:  2014-11       Impact factor: 1.214

Review 4.  Cerebrospinal fluid and plasma biomarkers in Alzheimer disease.

Authors:  Kaj Blennow; Harald Hampel; Michael Weiner; Henrik Zetterberg
Journal:  Nat Rev Neurol       Date:  2010-02-16       Impact factor: 42.937

5.  [Novel methods for dementia diagnostics].

Authors:  J Wiltfang
Journal:  Nervenarzt       Date:  2015-04       Impact factor: 1.214

6.  Cerebrospinal fluid biomarkers for dementia with lewy bodies.

Authors:  Elizabeta B Mukaetova-Ladinska; Rachael Monteith; Elaine K Perry
Journal:  Int J Alzheimers Dis       Date:  2010-10-17

7.  CSF Biomarkers for Alzheimer's Disease Diagnosis.

Authors:  A Anoop; Pradeep K Singh; Reeba S Jacob; Samir K Maji
Journal:  Int J Alzheimers Dis       Date:  2010-06-23

8.  Phosphorylated tau as a candidate biomarker for amyotrophic lateral sclerosis.

Authors:  Murray Grossman; Lauren Elman; Leo McCluskey; Corey T McMillan; Ashley Boller; John Powers; Katya Rascovsky; William Hu; Les Shaw; David J Irwin; Virginia M-Y Lee; John Q Trojanowski
Journal:  JAMA Neurol       Date:  2014-04       Impact factor: 18.302

Review 9.  Rethinking on the concept of biomarkers in preclinical Alzheimer's disease.

Authors:  Valentina Berti; Cristina Polito; Gemma Lombardi; Camilla Ferrari; Sandro Sorbi; Alberto Pupi
Journal:  Neurol Sci       Date:  2016-01-20       Impact factor: 3.307

Review 10.  Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.

Authors:  Piotr Lewczuk; Peter Riederer; Sid E O'Bryant; Marcel M Verbeek; Bruno Dubois; Pieter Jelle Visser; Kurt A Jellinger; Sebastiaan Engelborghs; Alfredo Ramirez; Lucilla Parnetti; Clifford R Jack; Charlotte E Teunissen; Harald Hampel; Alberto Lleó; Frank Jessen; Lidia Glodzik; Mony J de Leon; Anne M Fagan; José Luis Molinuevo; Willemijn J Jansen; Bengt Winblad; Leslie M Shaw; Ulf Andreasson; Markus Otto; Brit Mollenhauer; Jens Wiltfang; Martin R Turner; Inga Zerr; Ron Handels; Alexander G Thompson; Gunilla Johansson; Natalia Ermann; John Q Trojanowski; Ilker Karaca; Holger Wagner; Patrick Oeckl; Linda van Waalwijk van Doorn; Maria Bjerke; Dimitrios Kapogiannis; H Bea Kuiperij; Lucia Farotti; Yi Li; Brian A Gordon; Stéphane Epelbaum; Stephanie J B Vos; Catharina J M Klijn; William E Van Nostrand; Carolina Minguillon; Matthias Schmitz; Carla Gallo; Andrea Lopez Mato; Florence Thibaut; Simone Lista; Daniel Alcolea; Henrik Zetterberg; Kaj Blennow; Johannes Kornhuber
Journal:  World J Biol Psychiatry       Date:  2017-10-27       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.